טוען...
Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
The small GTPase KRAS, which is frequently mutated in human cancers, must be localized to the plasma membrane (PM) for biological activity. We recently showed that the KRAS C-terminal membrane anchor exhibits exquisite lipid-binding specificity for select species of phosphatidylserine (PtdSer). We,...
שמור ב:
| הוצא לאור ב: | Life Sci Alliance |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Life Science Alliance LLC
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6709719/ https://ncbi.nlm.nih.gov/pubmed/31451509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.26508/lsa.201900431 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|